Survival Analysis: A Practical Approach: Second Edition

Survival Analysis: A Practical Approach: Second Edition

Volumn , Issue , 2006, Pages 1-266

  Machin, David ^a,b,c   Cheung, Yin Bun ^a,d   Parmar, Mahesh KB ^e,f  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e MRC CLINICAL TRIALS UNIT   (United Kingdom)

^f UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889402962     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470034572     Document Type: Book

References (102)

1. Aboulker JP and Swart AM (1993). Preliminary analysis of the Concorde Trial. Lancet, 341, 889-890. [1]
2. Advanced Ovarian Cancer Trialists' Group (1991). Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. British Medical Journal, 303, 884-893. [10]
3. Allison PD (1995). Survival Analysis Using the SAS System: A Practical Guide. SAS Institute Inc, Cary, NC. [1]
4. Altman DG (1991). Practical Statistics for Medical Research. Chapman & Hall, London. [1]
5. Altman DG and de Stavola BL (1994). Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Statistics in Medicine, 13, 301-341. [7]
6. Altman DG, Lausen B, Sauerbrei W and Schumacher M (1994). Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. Journal of the National Cancer Institute, 86, 829-835 and 1798-1799. [6]
7. Altman DG, Machin D, Bryant TN and Gardner MJ (eds) (2000). Statistics with Confidence. British Medical Association, London. [1]
8. Altman DG and Royston P (2000). What do we mean by validating a prognostic model? Statistics in Medicine, 11, 453-473. [8]
9. Ang ES-W, Lee S-T, Gan CS-G, See PG-J, Chan Y-H, Ng L-H and Machin D (2001). Evaluating the role of alternative therapy in burn wound management: randomized trial comparing most exposed burn ointment with conventional methods in the management of patients with second-degree burns. Medscape General Medicine, 6, 3 [1].
10. Bland M (2000). An Introduction to Medical Statistics (3rd edn). Oxford University Press, Oxford. [1]
11. Bleehen NM and Stenning SP on behalf of the Medical Research Council Brain Tumour Working Party (1991). A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. British Journal of Cancer, 64, 769-774. [5, 8]
12. Bonacini M, Louie S, Bzowej N and Wohl AM (2004). Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS, 18, 2039-2045. [1]
13. Bradburn MJ, Clark TG, Love SB and Altman DG (2003a). Survival Analysis Part II: Multivariate data analysis-an introduction to concepts and methods. British Journal of Cancer, 89, 431-436. [1]
14. Bradburn MJ, Clark TG, Love SB and Altman DG (2003b). Survival Analysis Part III: Multivariate data analysis-choosing a model and assessing its adequacy of fit. British Journal of Cancer, 89, 605-611. [1]
15. Campbell MJ, Machin D and Walters SJ (2006). Medical Statistics: A Commonsense Approach (4th edn). Wiley, Chichester. [1]
16. Capra M, Hewitt M, Hayward J, Weston CL, Machin D and Radford M. Long term outcome and cure in children with Hodgkin's lymphoma: The UKCCSG HD82 trial. (Submitted) [10]
17. Cheingsong-Popov R, Panagiotidi C, Bowcock S, Aronstam A, Wadsworth J and Weber J (1991). Relation between humoral responses to HIV gag and end proteins at seroconversion and clinical outcome of HIV infection. British Medical Journal, 302, 23-26. [3]
18. CheungYB (2000). Marital status and mortality in British women: a longitudinal study. International Journal of Epidemiology, 29, 93-99. [5, 6]
19. Cheung YB, Gao F and Khoo K-S (2003). Age at diagnosis and the choice of survival analysis methods in cancer epidemiology. Journal of Clinical Epidemiology, 56, 38-43. [7]
20. Cheung YB, Yip PSF and Karlberg JPE (2001a). Parametric modelling of neonatal mortality in relation to size at birth. Statistics in Medicine 20, 2455-2466. [2, 7]
21. Cheung YB, Yip PSF and Karlberg JPE (2001b). Fetal growth, early postnatal growth and motor development in Pakistani infants. International Journal of Epidemiology, 30, 66-74. [4]
22. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik, Laakso M, for the STOP-NIDDM Trial Research Group (2002). Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet, 359, 2072-2077. [1]
23. Chow PK-H, Tai B-C, Tan C-K, Machin D, Win K-M, Johnson PJ and Soo K-C (2002). Highdose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomised controlled trial. Hepatology, 36, 1221-1226 [2, 9].
24. Clark TG, Bradburn MJ, Love SB and Altman DG (2003a). Survival analysis part I: basic concepts and first analyses. British Journal of Cancer, 89, 232-238. [1]
25. Clark TG, Bradburn MJ, Love SB and Altman DG (2003b). Survival analysis part IV: further concepts and methods in survival analysis. British Journal of Cancer, 89, 781-786. [1]
26. Cleves MA, Gould WW and Gutierrez RG (2002). An Introduction to Survival Analysis Using STATA. Stata Press, College Station, TX. [1]
27. Collett D (2003). Modelling Survival Data in Medical Research (2nd edn). Chapman & Hall, London. [1, 4]
28. Coviello V and Boggess M (2004). Cumulative incidence estimation in the presence of competing risks. The Stata Journal, 4, 103-12. [10]
29. Cox DR (1972). Regression models and life tables (with discussion). Journal of the Royal Statistical Society, B34, 187-220. [1, 5]
30. Cox DR and Oakes D (1984). Analysis of Survival Data. Chapman & Hall, London. [1]
31. Donner A and Klar NS (2000). Design and Analysis of Cluster Randomisation Trials in Health Research. Arnold, London. [10]
32. Elashoff JD (2000). NQuery Advisor Version 4.0 User's Guide. Los Angeles, CA. [1, 9]
33. Farewell VT (1979). An application of Cox's proportional hazards model to multiple infection data. Applied Statistics, 28, 136-143. [7]
34. Farley TMM, Ali MM and Slaymaker E (2001). Competing approaches to analysis of failure times with competing risks. Statistics in Medicine, 20, 3601-3610. [10]
35. Farley TMM, Rosenberg MJ, Rowe PJ, Chen J-H and Meirik O (1992). Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet, 339, 785-788. [2]
36. Fisher B, Anderson S, Fisher ER, Redmond C, Wickerham DL, Wolmark N, Mamounas EP, Deutsch M and Margolese R (1991). Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet, 338, 327-331. [5, 7]
37. Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (2002). Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumour recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. Journal of Clinical Oncology, 20, 4141-4149. [10]
38. France LA, Lewis JA and Kay R (1991). The analysis of failure time data in crossover studies. Statistics in Medicine, 10, 1099-1113. [10]
39. Gray R, James R, Mossman J and Stenning SP (1991). AXIS: a suitable case for treatment. British Journal of Cancer, 63, 841-845. [5]
40. Hankey GJ, Slattery JM and Warlow CP (1991). Prognosis and prognostic factors of retinal infarction: a prospective cohort study. British Medical Journal, 302, 499-504. [2]
41. Hayes RJ, Alexander ND, Bennett S and Cousens SN (2000). Design and analysis issues in clusterrandomized trials of interventions against infectious diseases. Statistical Methods in Medical Research, 9, 95-116. [7]
42. Kalbfleisch JD and Prentice RL (2002). The Statistical Analysis of Failure Time Data (2nd edn). Wiley, New York. [1]
43. Kaplan EL and Meier P (1958). Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481. [1, 2]
44. Kelly PJ and Lim LLY (2000). Survival analysis for recurrent event data: an application to childhood infectious diseases. Statistics in Medicine, 19, 13-33. [10]
45. Khawaja HT, Campbell MJ and Weaver PC (1988). Effect of transdermal glyceryl trinitrate on the survival of peripheral intravenous infusions: a double-blind prospective clinical study. British Journal of Surgery, 75, 1212-1215. [2]
46. Korenman S, Goldman N, Fu H (1997). Misclassification bias in estimates of bereavement effects. American Journal of Epidemiology, 145, 995-1002. [6, 7]
47. Leonard RCF, Hayward RL, Prescott RJ and Wang JX (1991). The identification of discrete prognostic groups in low-grade non-Hodgkin's lymphoma. Annals of Oncology, 2, 655-662. [8]
48. Mackie RM, Bufalino R, Morabito A, Sutherland C and Cascinelli N for the World Health Organization Melanoma Programme (1991). Lack of effect of pregnancy on outcome of melanoma. Lancet, 337, 653-655. [7]
49. Machin D and Campbell MJ (2005). Design of Studies for Medical Research. Wiley, Chichester. [1]
50. Machin D, Campbell MJ, Fayers PM and Pinol APY (1997). Statistical Tables for the Design of Clinical Trials (2nd edn). Blackwell Scientific Publications, Oxford. [1, 9]
51. Maldonado G, Greenland S (1993). Simulation study of confounder-selection strategies. American Journal of Epidemiology, 138, 923-936. [6]
52. Marubini E and Valsecchi MG (1995). Analysing Survival Data from Clinical Trials and Observational Studies. Wiley, Chichester. [1]
53. Mayo NE, Korner-Bitensky NA and Becker R (1991). Recovery time at independent function poststroke. American Journal of Physical Medicine and Rehabilitation, 70, 5-12. [1, 5]
54. McDiarmid T, Burns PN, Lewith GT and Machin D (1985). Ultrasound and the treatment of pressure sores: preliminary study. Physiotherapy, 71, 66-70. [3]
55. McIllmurray MB and Turkie W (1987). Controlled trial of γ linolenic acid in Dukes' C colorectal cancer. British Medical Journal, 294, 1260; 295, 475. [2, 4]
56. Medical Research Council Brain Tumour Working Party (1990). Prognostic factors for malignant glioma: development of a prognostic index. Journal of Neuro-Oncology, 9, 47-55. [8]
57. Medical Research Council Lung Cancer Working Party (1989a). Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer. Respiratory Medicine, 83, 51-58. [5]
58. Medical Research Council Lung Cancer Working Party (1989b). Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. British Journal of Cancer, 59, 584-590. [5]
59. Medical Research Council Lung Cancer Working Party (1991). Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. British Journal of Cancer, 63, 265-270. [5]
60. Medical Research Council Lung Cancer Working Party (1992). A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. British Journal of Cancer, 65, 934-941. [5]
61. Medical Research Council Lung Cancer Working Party (1993). A randomised trial of 3 or 6 courses of etoposide, cyclophosphamide, methotrexate and vincristine, or 6 courses of etoposide and ifosfamide in small-cell lung cancer (SCLC). I: Survival and prognostic factors. British Journal of Cancer, 68, 1150-1156. [5, 7]
62. Medical Research Council Lung Cancer Working Party (1996). The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. British Journal of Cancer, 74, 632-639. [3]
63. Medical Research Council Working Party on Advanced Carcinoma of the Cervix (1993). A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiotherapy and Oncology, 26, 93-103. [3, 4]
64. Medical Research Council Working Party on Misonidazole in Gliomas (1983). A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of grades 3 and 4 astrocytomas. British Journal of Radiology, 56, 673-682. [5, 6, 8]
65. Meng CD, Zhu JC, Chen ZW, Wong LT, Zhang GY, Hu YZ, Ding JH, Wang XH, Qian SZ, Wang C, Machin D, Pinol A and Waikes GMH (1988). Recovery of sperm production following the cessation of gossypol treatment: a two centre study in China. International Journal of Andrology, 11, 1-11. [1, 5]
66. Moffatt CJ, Franks PJ, Oldroyd M, Bosanquet N, Brown P, Greenhalgh RM and McCollum CN (1992). Community clinics for leg ulcers and impact on healing. British Medical Journal, 305, 1389-1392. [2]
67. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ and Machin D (1985). Myelodysplastic syndromes: a scoring system with prognostic significance. British Journal of Haematology, 59, 425-433. [3]
68. Nash TP, Williams JD, Machin D (1990). TENS: does the type of stimulus really matter? Pain Clinic, 3, 161-168. [3]
69. Nolan T, Debelle G, Oberklaid F and Coffey C (1991). Randomised trials of laxatives in treatment of childhood encopresis. Lancet, 338, 523-527. [10]
70. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GL, Sollano A, Shannon J, Tandon PK and DeMets DL for the PROMISE Study Research Group (1991). Effect of oral milrinone on mortality in severe chronic heart failure. New England Journal of Medicine, 325, 1468-1475. [1, 3]
71. Peto J (1984). The calculation and interpretation of survival curves. In: Buyse ME, Staquet MJ and Sylvester RJ (eds), Cancer Clinical Trials. Methods and Practice. Oxford University Press, Oxford, pp. 361-380. [2]
72. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, MacPherson K, Peto J and Smith PG (1976). Design and analysis of randomised clinical trials requiring prolonged observation of each patient. I: introduction and design. British Journal of Cancer, 34, 585-612. [1]
73. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, MacPherson K, Peto J and Smith PG (1977). Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II: Analysis and examples. British Journal of Cancer, 35, 1-39. [1]
74. Peduzzi P, Concato J, Kemper E, Holford TR and Feinstein AR (1996). A simulation study of the number of events per variable in logistic regression analysis. Journal of Clinical Epidemiology, 49, 1372-1379. [9]
75. Piffarré A, Rosell R, Monzó M, De Anta JM, Moreno I, Sánchez JJ, Ariza A, Mate JL, Martínez E and Sánchez M (1997). Prognostic value of replication errors on chromosomes 2p and 3p in non-small-cell lung cancer. British Journal of Cancer, 75, 184-189. [9]
76. Pocock SJ, Clayton TC and Altman DG (2002). Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet, 359, 1686-1689. [1]
77. Poon D, Yap S-P, Wong Z-W, Cheung Y-B, Leong S-S, Wee J, Tan T, Fong K-W, Chua E-T and Tan E-H (2004). Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma. International Journal of Radiation Oncology, Biology and Physics, 59, 1312-1318. [4]
78. Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov BD, Ene-lordache B, Gherardi G, Group (2004). Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet, 364, 503-512. [6]
79. Samanta A, Roy S and Woods KL (1991). Gold therapy in rheumatoid arthritis. Lancet, 338, 642. [2]
80. Samuelson SO and Kongerud J (1994). Interval censoring in longitudinal data of respiratory symptoms in aluminium workers: a comparison of methods. Statistics in Medicine, 13, 1771-1780. [5, 6]
81. Sauerbrei W, Royston P, Bojar H, Schmoor C and Schumacher M (1999). Modelling the effects of standard prognostic factors in node-negative breast cancer. British Journal of Cancer, 79, 1752-1760. [8]
82. Schoenfeld D (1982). Partial residuals for the proportional hazards regression model. Biometrika, 69, 239-241. [5]
83. Shuster JJ (199l). Median follow-up in clinical trials. Journal of Clinical Oncology, 9, 191-192. [2]
84. Sposto R (2000). Cure model analysis in cancer: an application to data from the Children's Cancer Group. Statistics in Medicine, 21, 293-312. [10]
85. StataCorp (2005). Stata Statistical Software: Release 9.0. StataCorp LP, College Station, Tx. [4, 10]
86. Stephens RJ, Girling DJ and Machin D (1994). Can patients at risk from death during treatment for small-cell lung cancer be identified? Lung Cancer, 11, 259-274. [2]
87. Sun GW, Shook TL and Kay GL (1996). Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. Journal of Clinical Epidemiology, 49, 907-916. [6]
88. Tai B-C, Peregoudov A and Machin D (2001). A competing risk approach to the analysis of trials of alternative intrauterine devices (IUDs) for fertility regulation. Statistics in Medicine, 20, 3589-3600. [10]
89. Tai B-C, White I, Gebski V and Machin D (2001). Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. Statistics in Medicine, 20, 661-684. [10]
90. Tan C-K, Law N-M, Ng N-S and Machin D (2003). Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation. Journal of Clinical Oncology, 21, 2294-2298. [8, 9]
91. The RISC Group (1990). Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet, 336, 827-830. [3, 5]
92. Therneau TM and Grambsch PM (2000). Modeling Survival Data: Extending the Cox Model. Springer- Verlag, New York. [5]
93. Turnbull BW, Brown BW Jr and Hu M (1974). Survivorship analysis of heart transplant data. Journal of the American Statistical Association, 69, 74-86. [1, 2, 7]
94. Umen AJ and Le CT (1986). Prognostic factors, models and related statistical problems in the survival of end-stage renal disease patients on haemodialysis. Statistics in Medicine, 5, 637-652. [6]
95. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nyström P and Bylock A (2003). Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet, 362, 789-797. [1]
96. Valerius NH, Koch C and Hoiby N (1991). Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet, 338, 725-726. [9]
97. Venables WN and Ripley BD (1999). Modern Applied Statistics with S-Plus (3rd edn). Springer-Verlag, New York. [1]
98. Van Griensven GJP, Boucher EC, RoosMand Coutinho RA (1991). Expansion of AIDS case definition. Lancet, 338, 1012-1013. [2]
99. Weston CL, Douglas C, Craft A, Lewis IJ, and Machin D (2004). Establishing long term survival and cure in young patients with Ewing's sarcoma. British Journal of Cancer, 91, 225-232. [10]
100. World Health Organization Task Force on Long-acting Systemic Agents for Fertility Regulation. Special Programme of Research, Development and Research training in Human Reproduction (1988). A multicentred phase III comparative study of two hormonal contraceptive preparations given oncea- month by intramuscular injections. 1: contraceptive efficacy and side effects. Contraception, 37, 1-20. [3]
101. World Health Organization Task Force on Long-acting Systemic Agents for Fertility Regulation (1990). Microdose intravaginal levenorgestrel contraception: a multicentre clinical trial. III. The relationship between pregnancy rate and body weight. Contraception, 41, 143-150. [3]
102. Yudkin PL, Ellison GW, Chezzi A, Goodkin DE, Hughes RAC, McPherson K, Mertin J and Milanese C (1991). Overview of aziathioprine treatment in multiple sclerosis. Lancet, 338, 1051-1055. [10]